← Peptide library

Peptide comparison

Tirzepatide vs Semaglutide

Tirzepatide vs Semaglutide

This page compares tirzepatide and semaglutide side by side, drawing on reconstitution and dosing-reference data for both. It lays out each compound’s regulatory status, evidence tier, route of administration, dosing frequency, and the dose range cited in current labeling. The information is presented for reference only and is not medical advice or a recommendation to use either product.

Tirzepatide

Semaglutide

Regulatory status

Regulatory status

FDA-approved prescription for labeled indications

FDA-approved prescription for labeled indications

Evidence tier

Evidence tier

Current regulator label

Current regulator label

Route

Route

Subcutaneous

Subcutaneous

Frequency

Frequency

Once weekly

Once weekly

Study / label range

Study / label range

2.5–15 mg

0.25–2.4 mg

Key differences

Both tirzepatide and semaglutide are FDA-approved prescription products for their labeled indications, and the figures shown here are drawn from the current regulator label evidence tier for each. Both are administered subcutaneously and dosed once weekly. They differ in dose range: the tirzepatide reference range is 2.5-15 mg, with starting at 2.5 mg weekly and labeled maintenance options of 5, 10, or 15 mg weekly (maximum 15 mg), while the semaglutide reference range is 0.25-2.4 mg. For semaglutide, the Wegovy label describes 0.25 mg weekly during weeks 1-4, then 0.5, 1.0, and 1.7 mg, with a usual maintenance of 2.4 mg. These ranges reflect the labels themselves and are not guidance on what dose to take or which product to choose; dosing decisions belong with a licensed prescriber.

Open Tirzepatide calculator

Open Semaglutide calculator

Tirzepatide reference

Semaglutide reference

Reference comparison only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol.

Frequently asked questions

How are tirzepatide and semaglutide administered?

Both are given subcutaneously, once weekly, according to their current regulator labels. The table above shows each compound’s route and frequency side by side.

What dose ranges does this comparison reference?

It uses the labeled reference ranges shown above — tirzepatide 2.5–15 mg and semaglutide 0.25–2.4 mg. These are label ranges quoted for reference, not dosing recommendations.

Can I calculate reconstitution for both here?

Yes. Open either compound’s calculator from the buttons above to work out its concentration (mg/mL), draw volume and U-100 syringe units. The arithmetic is the same for both.

Does this page recommend one over the other?

No. It is a neutral, label-based reference. It does not assess efficacy, safety, or which product is appropriate for anyone — those decisions belong with a licensed prescriber.